MOLNMOLECULAR PARTNERS AG

Nasdaq molecularpartners.com


$ 7.90 $ -0.27 (-3.3 %)    

Thursday, 01-Aug-2024 15:47:26 EDT
QQQ $ 457.21 $ -16.67 (-3.52 %)
DIA $ 403.27 $ -5.22 (-1.28 %)
SPY $ 542.12 $ -8.69 (-1.58 %)
TLT $ 95.61 $ 0.55 (0.58 %)
GLD $ 225.83 $ -0.72 (-0.32 %)
$ 8.58
$ 8.17
$ 7.80 x 100
-- x --
$ 7.80 - $ 9.12
$ 3.32 - $ 12.70
445,374
na
311.92M
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Market-Moving News for June 14th
06/14/2024 12:34:25

ADBE: 16% | Adobe shares are trading higher following better-than-expected Q2 earnings and strong guidance. BPTH: 46% | Bio-Pa...

 molecular-partners-reveals-preclinical-data-for-first-switch-darpin-candidate-mp0621-at-eha-2024

Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activat...

Core News & Articles
Market-Moving News for June 11th
06/11/2024 12:29:09

MOLN: 11% | Molecular Partners shares are trading higher after the company announced the debut of their lead Raido-DARPin thera...

 reported-saturday-molecular-partners-presented-data-from-completed-phase-1-trial-of-mp0317-monotherapy-in-advanced-solid-tumors-at-asco-2024

Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironment Favor...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION